Jetema signs ₩30.2bn drug supply contract with domestic distributor
Jetema filed a supply contract, Pharmaceutical (Botulinum Toxin) Exclusive Supply, with a domestic distribution company. The contract amount is ₩30.2bn, reported as 39.7% of revenue, for a period from Oct 14, 2026 to Oct 14, 2031.
Key facts
| Contract name | Pharmaceutical (Botulinum Toxin) Exclusive Supply |
|---|---|
| Counterparty | Domestic distribution company |
| Contract amount | ₩30.2bn |
| % of revenue (as reported) | 39.7% |
| Period start | Oct 14, 2026 |
| Period end | Oct 14, 2031 |
Comparison
| Amount as % of FY2025 revenue (calculated) | 39.2% |
|---|---|
| Revenue 2025 | ₩76.9bn |
| Revenue 2024 | ₩68.5bn |
| Revenue 2023 | ₩58.7bn |
Context
In the 12 months before this filing, Jetema filed 2 supply contracts totaling ₩34.9bn. By our calculation, this contract equals 39.2% of FY2025 revenue of ₩76.9bn.
Key metrics
Supply contracts
| Supply contracts, last 12 months | ₩75.1bn |
|---|---|
| Supply contracts vs prior-year revenue | 97.6% |
| Contracts without a KRW amount | 0 contracts without a KRW amount excluded |
Related filings
Source: DART (Financial Supervisory Service) · Original filing on DART ↗